TY - JOUR
T1 - End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004
AU - Lucas, Gregory M.
AU - Mehta, Shruti H.
AU - Atta, Mohamed G.
AU - Kirk, Gregory D.
AU - Galai, Noya
AU - Vlahov, David
AU - Moore, Richard D.
PY - 2007/12
Y1 - 2007/12
N2 - BACKGROUND: HIV-infected African-Americans are at increased risk of end-stage renal disease requiring renal replacement therapy (RRT). OBJECTIVES: To compare the incidence of RRT in HIV-infected and HIV-seronegative African-Americans and describe temporal trends in RRT and chronic kidney disease (CKD) in HIV infection. DESIGN: Cohort study in Baltimore including 4509 HIV-infected and 1746 HIV-seronegative African-Americans. METHODS: Incident RRT was defined by matching participant identifiers with the US Renal Data System; CKD was defined as an estimated glomerular filtration rate < 60 ml/min per 1.73m for ≥ 3 months. Standardized incidence ratios (SIR) and 95% confidence intervals (CI) were calculated by indirect adjustment. Risk factors for RRT were assessed by person-time methods and Poisson regression. RESULTS: RRT was initiated in 24 HIV-seronegative subjects over 13 415 person-years of follow-up (SIR, 2.3; 95% CI, 1.5-3.4), in 51 HIV-infected participants without AIDS over 10 780 person-years (SIR, 6.9; 95% CI, 5.1-9.0), and in 125 participants with AIDS over 9833 person-years. SIR, 16.1; 95% CI, 13.4-19.2). In HIV-infected African-Americans, RRT incidences were 5.8 and 9.7/1000 person-years in the pre-HAART and HAART eras, respectively (adjusted rate ratio 1.2; 95% CI, 0.8-1.9). In supplementary analyses, CKD incidence declined significantly in the HAART era compared with pre-HAART, but the CKD period prevalence increased. CONCLUSIONS: Nearly 1% of HIV-infected African-Americans initiated RRT annually, a rate that was similar in the HAART and pre-HAART eras. While new cases of CKD decreased, the prevalence of CKD increased in the HAART era, primarily because survival in those with HIV-associated CKD has improved.
AB - BACKGROUND: HIV-infected African-Americans are at increased risk of end-stage renal disease requiring renal replacement therapy (RRT). OBJECTIVES: To compare the incidence of RRT in HIV-infected and HIV-seronegative African-Americans and describe temporal trends in RRT and chronic kidney disease (CKD) in HIV infection. DESIGN: Cohort study in Baltimore including 4509 HIV-infected and 1746 HIV-seronegative African-Americans. METHODS: Incident RRT was defined by matching participant identifiers with the US Renal Data System; CKD was defined as an estimated glomerular filtration rate < 60 ml/min per 1.73m for ≥ 3 months. Standardized incidence ratios (SIR) and 95% confidence intervals (CI) were calculated by indirect adjustment. Risk factors for RRT were assessed by person-time methods and Poisson regression. RESULTS: RRT was initiated in 24 HIV-seronegative subjects over 13 415 person-years of follow-up (SIR, 2.3; 95% CI, 1.5-3.4), in 51 HIV-infected participants without AIDS over 10 780 person-years (SIR, 6.9; 95% CI, 5.1-9.0), and in 125 participants with AIDS over 9833 person-years. SIR, 16.1; 95% CI, 13.4-19.2). In HIV-infected African-Americans, RRT incidences were 5.8 and 9.7/1000 person-years in the pre-HAART and HAART eras, respectively (adjusted rate ratio 1.2; 95% CI, 0.8-1.9). In supplementary analyses, CKD incidence declined significantly in the HAART era compared with pre-HAART, but the CKD period prevalence increased. CONCLUSIONS: Nearly 1% of HIV-infected African-Americans initiated RRT annually, a rate that was similar in the HAART and pre-HAART eras. While new cases of CKD decreased, the prevalence of CKD increased in the HAART era, primarily because survival in those with HIV-associated CKD has improved.
KW - Antiretroviral therapy
KW - Chronic kidney disease
KW - Cohort study
KW - End-stage renal disease
KW - HIV infection
KW - Renal replacement therapy
UR - http://www.scopus.com/inward/record.url?scp=36349027007&partnerID=8YFLogxK
U2 - 10.1097/QAD.0b013e32827038ad
DO - 10.1097/QAD.0b013e32827038ad
M3 - Article
C2 - 18025880
AN - SCOPUS:36349027007
SN - 0269-9370
VL - 21
SP - 2435
EP - 2443
JO - AIDS
JF - AIDS
IS - 18
ER -